<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article116</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DIG" style="display:block; margin-bottom:10px;">DIG Original</a></li>
<h2><strong>DIG</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Mortality and Hospitalization in Heart Failure Patients on Digoxin". <br/>
The New England Journal of Medicine. Year Not Provided. Volume(Issue):Page Numbers Not Provided.<br/>
PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does digoxin therapy affect overall mortality and rate of hospitalization in patients with chronic heart failure and normal sinus rhythm?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Digoxin therapy did not reduce overall mortality in patients with chronic heart failure but was associated with a reduced rate of hospitalization both overall and for worsening heart failure, more precisely defining the role of digoxin in chronic heart failure management.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Despite digoxin being widely prescribed for heart failure treatment, uncertainties persisted about its long-term safety and efficacy. The study aimed to assess digoxin's impact on mortality and hospitalization over 3 to 5 years in patients with heart failure and normal sinus rhythm.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Not addressed in the provided article.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
In the main trial, patients had a left ventricular ejection fraction of 0.45 or less, while in the ancillary trial, patients possessed ejection fractions greater than 0.45.<br/>
<br/>
Inclusion Criteria<br/>
Chronic heart failure, left ventricular ejection fraction ≤0.45 for main or &gt;0.45 for ancillary trial, normal sinus rhythm.<br/>
<br/>
Exclusion Criteria<br/>
Not specified in the provided excerpt.<br/>
<br/>
Baseline Characteristics<br/>
No significant differences between digoxin and placebo groups.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to receive digoxin or placebo alongside diuretics and angiotensin-converting-enzyme inhibitors.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
In the primary trial, no significant difference in overall mortality between digoxin and placebo groups.<br/>
<br/>
Secondary Outcomes<br/>
In digoxin group compared to placebo: Fewer hospitalizations for worsening heart failure; trend toward a decrease in risk of death attributed to heart failure; reduction in hospitalizations for cardiovascular causes; increased suspected digoxin toxicity resulted in hospitalization (but low overall).<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was organized and conducted by a Steering Committee representing various institutions, with the drug and placebo supplied by Glaxo Wellcome.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Details not provided.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
